Immunogenicity of small‐cell lung cancer associates with <scp>STING</scp> pathway activation and is enhanced by <scp>ATR</scp> and <scp>TOP1</scp> inhibition

Abstract

Our study verifies that activation of the STING-IFN response by ATR and TOP1 inhibitors might be a therapeutic strategy to improve the response to immune checkpoint therapy in STING-low SCLC. Furthermore, the combinations of ATR and TOP1 inhibitors can augment tumor inflammation in STING-low SCLC.